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Abstract: A mutation in intron 26 of CEP290 (c.2991+1655A>G) is the most common 
genetic cause of Leber congenital amaurosis (LCA), a severe type of inherited retinal 
degeneration. This mutation creates a cryptic splice donor site, resulting in the insertion of 
an aberrant exon (exon X) into ~50% of all CEP290 transcripts. A humanized mouse 
model with this mutation did not recapitulate the aberrant CEP290 splicing observed in 
LCA patients, suggesting differential recognition of cryptic splice sites between species.  
To further assess this phenomenon, we generated two CEP290 minigene constructs, with 
and without the intronic mutation, and transfected these in cell lines of various species.  
RT-PCR analysis revealed that exon X is well recognized by the splicing machinery in 
human and non-human primate cell lines. Intriguingly, this recognition decreases in cell 
lines derived from species such as dog and rodents, and it is completely absent in Drosophila. 
In addition, other cryptic splicing events corresponding to sequences in intron 26 of 
CEP290 were observed to varying degrees in the different cell lines. Together, these results 
highlight the complexity of splice site recognition among different species, and show that 
care is warranted when generating animal models to mimic splice site mutations in vivo. 
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1. Introduction 
CEP290 encodes the CEntrosomal Protein of 290 kDa, a protein that is thought to play an important 
role in ciliogenesis and/or ciliary transport, in many different cell types including retinal photoreceptor 
cells [1–3]. Mutations in CEP290 gene have been associated with a wide range of ciliopathies,  
ranging from lethal syndromes (Meckel-Grüber syndrome MIM#611134) to non-syndromic retinal 
degeneration (Leber congenital amaurosis MIM#611755) [4–7]. Leber congenital amaurosis (LCA) is 
an early-onset severe form of visual impairment that can be caused by mutations in either one of  
at least 22 different genes (RetNet: https://sph.uth.edu/retnet). Interestingly, mutations in CEP290 
underlie approximately 20% of the cases, with a recurrent intronic mutation (c.2991+1655A>G) 
accounting for up to 15% of all LCA cases in some European and North-American populations [5,8]. 
This deep-intronic CEP290 mutation creates a splice donor site that allows the insertion of a 128-bp 
cryptic exon to approximately 50% of the CEP290 transcripts, resulting in premature termination of 
protein synthesis [5,9]. 
The generation of a mature mRNA molecule involves multiple steps. First, DNA is transcribed to 
pre-mRNA, and subsequently the splicing machinery carefully removes the introns to produce a 
mature mRNA that will be translated by the ribosomes [10,11]. Several signal sequences throughout the  
pre-mRNA direct the binding of proteins of the spliceosome [10,12]. Mainly, exon-intron boundaries 
are delimited by consensus splice donor and acceptor sequences. However, besides these canonical 
sequences, other signals such as enhancers or repressors, as well as non-canonical signals can lead to 
the excision or inclusion of an exon, leading to what is called alternative splicing. This process 
increases the complexity of gene expression and allows the generation of multiple protein products 
derived from the same gene [11–13]. In addition, the secondary structure of the pre-mRNA can play an 
important role in the accessibility of splice factors and thereby regulate splicing [14]. 
Besides naturally occurring alternative splicing, genetic mutations can also alter the composition of 
mRNA molecules. Several mutations in the exon-intron boundaries that result in exon skipping or 
intron retention are known to underlie a plethora of different inherited conditions, including retinal 
degeneration [15]. In addition, deep-intronic mutations may activate cryptic splice acceptor or donor 
sites, resulting in the insertion of so-called pseudo-exons to the final mRNA transcript, often leading to 
premature termination of the corresponding protein [15]. One of the most recurrent examples of  
these is the aforementioned deep-intronic mutation in CEP290 (c.2991+1655A>G) that generates  
a splice donor site resulting in the insertion of a cryptic exon (coined exon X) into ~50% of the 
CEP290 mRNA transcripts [5]. 
Recently, we generated a humanized mouse model carrying this intronic mutation in order to mimic 
the molecular and phenotypic characteristics of CEP290-associated LCA. Unfortunately, this model 
did not recapitulate the aberrant CEP290 splicing that we observe in LCA patients with this  
mutation [16]. On one hand, exon X was inserted into only a small proportion of Cep290 transcripts in 
the retina of the transgenic mice, whereas in addition, a second cryptic exon (exon Y) within the 
human intron 26 of CEP290 was spliced into part of the Cep290 transcripts. The total amount of 
aberrant Cep290 transcripts (containing either exon X, exon Y or exons X + Y) did not exceed ~15% 
of the total pool of Cep290 transcripts, and therefore did not result in any signs of retinal degeneration 
in our mouse model [16]. Together, these data suggested a differential recognition of cryptic splice 
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sites between species. Here, we further studied this phenomenon, and show that the recognition of the 
cryptic exon introduced by the c.2991+1655A>G mutation in CEP290 indeed is species-dependent, 
and seems to correlate to the evolutionary distance to humans. In addition, we show that strengthening 
the splice acceptor and donor sites of exon X by site-directed mutagenesis allows an efficient 
recognition of exon X in murine cells, highlighting the differences between the human and murine 
splicing machineries, and thereby providing important insights in how to study human phenotypes caused 
by splice site mutations. 
2. Results 
2.1. Generation and Validation of CEP290 Minigenes 
In order to evaluate whether the recognition of the cryptic splice donor site that is activated by  
the c.2991+1655A>G mutation in CEP290 indeed is species-dependent, two CEP290 minigenes 
encompassing the genomic region between exons 26 and 27 of CEP290 under the control of the 
cytomegalovirus (CMV) immediate-early promoter were generated; one of them was carrying the  
c.2991+1655A>G mutation (Figure 1A). To assess whether transfection of these minigene constructs 
recapitulates the splice pattern observed in individuals with CEP290-associated LCA, human 
embryonic kidney cells (HEK293T) and human retinal pigmented epithelium cells (hTERT-RPE1) were 
transfected. RT-PCR analysis revealed that transfection of the LCA CEP290 minigene resulted in the 
exact same transcript composition as the one observed in patient-derived fibroblast cells, demonstrating 
the suitability of this cellular system to assess CEP290 pre-mRNA splicing (Figure 1A, Supplementary 
Figure S1A). 
2.2. Assessment of Cryptic Splice Events in Different Species 
In the humanized LCA mouse model Cep290lca/lca, exon X was only poorly recognized by the 
murine splicing machinery. In addition, a new aberrant exon (exon Y) residing in intron 26 of CEP290 
(Figure 1A) was included in a small proportion of the CEP290 transcripts, both in the Cep290lca/lca as 
well as in the humanized control Cep290hum/hum model [16]. To study the recognition of the splice site 
sequences that define these aberrant exons by the splicing machinery of different organisms, cell lines 
from various species (listed in Table 1) were transfected with either the WT or the LCA minigene 
construct. A series of dedicated RT-PCR analysis (with primers located in exon 26, exon X, exon Y and 
exon 27, Figure 1B) was performed, followed by Sanger sequencing analysis of all the PCR products 
that were identified on gel, and semiquantitative analysis of all the bands. PCR analysis with primers 
26_F and 27_R revealed that in all species, the majority of CEP290 transcripts represented the  
wild-type mRNA with a minimal insertion of cryptic exons. Only in the human and monkey-derived 
cell lines transfected with the LCA minigene, a robust insertion of a cryptic exon was observed, 
therefore most likely representing exon X (Figure 1B, upper panel and Supplementary Figure S1B, 
upper graph). In a more dedicated analysis using primers located inside the cryptic exons, transcripts 
containing exon X were detected in primate-derived cell lines but were also identified in cell lines 
from pig, dog, hamster and mouse but not the fruit fly. In contrast, exon Y-containing transcripts were 
only barely detectable in human, primate and porcine cell lines, whereas canine and rodent cells 
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showed a high recognition of exon Y. In Drosophila, this cryptic exon Y was also not recognized 
(Figure 1B and Supplementary Figure S1B). Following Sanger sequencing analysis of the PCR 
products, a third cryptic exon, coined exon Z, was identified, located downstream of exon Y (Figure 1A). 
This exon was recognized by the splicing machinery in cell lines of all species, but mostly in the  
dog and rodent cells, without major differences between WT and LCA constructs (Figure 1B and 
Supplementary Figure S1B). The occurrence of exon Z was subsequently also tested in fibroblast cells 
derived from a patient with the intronic CEP290 mutation but no exon Z-containing transcripts were 
amplified. In the retinas of the humanized mouse models (Cep290lca/lca and Cep290hum/hum) however, 
trace amounts of exon Z-containing transcripts were found (data not shown), indicating that the 
inclusion of exon Z, albeit in very low levels, is not an artifact solely caused by the overexpression of 
the minigene. In the PCR analysis using primers Z_F and 27_R, a ~300-bp PCR product was identified 
in some samples. Sequence analysis revealed that this product represented a part of intron 26 (just 
upstream of exon X, the sequence of exon X and part of the sequence of exon 27). Due to the high 
degree of sequence identity between the primer-binding region of exon Z, and another region in  
intron 26, in those cell lines that express a high amount of exon X-containing CEP290 transcripts  
(i.e., human, monkey), apparently this product is efficiently amplified. None of these intron-retaining 
transcripts however were found in the patient-derived cells or in the retinas of the humanized mouse 
models (data not shown), suggesting that these products are the result of the overexpression of the 
minigene constructs and therefore have no physiological relevance. 
2.3. Identification of a Suitable Sequence to Increase the Recognition of Exon X in Mouse 
Having studied the species-dependent recognition of cryptic CEP290 exons in detail, we next  
aimed to assess whether further modification of important splice site sequences would increase the 
recognition of cryptic exon X in mouse cells. A comparison of the acceptor and donor splice site 
sequences of exon X to the mammalian consensus sequence highlighted a few differences (Figure 2A). 
In order to make the acceptor and donor splice sites of exon X more similar to the consensus sequence, 
we performed site-directed mutagenesis, generating three additional minigene constructs. The first one 
(LCA-m1) included two changes in the splice acceptor site (at position −3T>C and +1T>G), in a second 
one (LCA-m2) the last nucleotide of the exon was changed (−1T>G), and the final construct combined 
these changes (LCA-m1/m2) (Figure 2B). 
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Figure 1. Assessment of CEP290 splicing upon overexpression of the minigenes in cells 
from different species. (A) Upper panel: Schematic representation of the position of the 
promoter and different cryptic exons within intron 26, as well as the primer localization in 
the wild-type (WT) and Leber congenital amaurosis (LCA), minigene construct carrying 
the intronic mutation; Lower panel: Splicing pattern detected after minigene expression in 
human HEK293T and hTERT-RPE1 cells compared to fibroblast cell lines of a healthy 
individual or an individual homozygously carrying the intronic CEP290 mutation;  
(B) Assessment of the splicing pattern of WT and LCA minigenes in several cell lines of 
different species via RT-PCR analysis. Actin (ACT) and rhodopsin (RHO) were used to 
normalize samples. MQ represents milli-Q water and was the negative control of the PCR 
reaction. For semiquantitative analysis of the gels, see Supplementary Figure S1. 
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Table 1. Oligonucleotide sequences. 
Name Forward Primers (Sequence 5'–3') 
Act_F ACTGGGACGACATGGAGAAG 
Rho_F ATCTGCTGCGGCAAGAAC 
CEP290_attB1_i25_F GGGGACAAGTTTGTACAAAAAAGCAGGCTTCGGCCGCTCTTTCTCAAAAGTGGC 
CEP290_m1_F GCCCGGCTAATTTTTTGTATTTTCAGGAGAGATGGGGTTTCACCTTG 
CEP290_m2_F CACCTGGCCCCAGTTGTAATGGTGAGTATCTCATACCTATCCC 
CEP290__F TGCTAAGTACAGGGACATCTTGC 
CEP290_X_F GCACCTGGCCCCAGTTG 
CEP290_Y_F CATAGCTCATTGCAGCCTTG 
CEP290_Z_F TGCCTCAGTCTCCTGAGTAG 
 Reverse Primers (Sequence 5'–3') 
Act_R TCTCAGCTGTGGTGGTGAAG 
Rho_R AGGTGTAGGGGATGGGAGAC 
CEP290_attB2_i27_R GGGGACCACTTTGTACAAGAAAGCTGGGTGCTTGGTGGGGTTAAGTACAGG 
CEP290_m1_R CAAGGTGAAACCCCATCTCTCCTGAAAATACAAAAAATTAGCCGGGC 
CEP290_m2_R GGGATAGGTATGAGATACTCACCATTACAACTGGGGCCAGGTG 
CEP290_27_R AGACTCCACTTGTTCTTTTAAGGAG 
Following site-directed mutagenesis, the five different minigene constructs (WT, LCA, LCA-m1, 
LCA-m2 and LCA-m1/m2) were transfected in two cell lines of human (HEK293 and hTERT-RPE1) 
and two cell lines of mouse (mIMCD-3 and BL16-F10) origin. RT-PCR analysis using primers located 
in exon 26 and exon 27 revealed that in the human cell lines, strengthening either the acceptor or  
the donor site of exon X already resulted in a clear increase of aberrant transcripts (Figure 2C and 
Supplementary Figure S2A,B). Similar effects were also observed in monkey COS1 cells (data not 
shown). In contrast, in the mouse cell lines, an obvious increase in aberrant transcripts is only observed 
if both splice sites are modified, whereas only a minor shift was observed if only one of the two was 
mutated (Figure 2C and Supplementary Figure S2A,B). When the primer was specifically located in 
exon X, the previous results were supported by an increasing amount of exon X detected in the human 
cell lines. Interestingly, in the mouse cell lines, the levels of exon X-containing transcripts without any 
other cryptic exons (i.e., exons Y and/or Z) only increased if both the splice acceptor (m1) as well as 
the splice donor (m2) site of exon X are mutated (Figure 2C and Supplementary Figure S2B), 
supporting the fact that the increased aberrant transcripts detected in PCR from exon 26 to exon 27 
included the cryptic exon X. These data again highlight the differences in splice site recognition 
between humans and mice, but also show that by site-directed mutagenesis of splice site sequences, it 
is possible to modulate the recognition of cryptic exons in different species. 
  
Int. J. Mol. Sci. 2015, 16 5291 
 
 
 
Figure 2. Evaluation of the modification of the splice sites of exon X. (A) Sequence 
alignment of the splice site sequences of exon X with the consensus canonical acceptor  
and donor splice sites; (B) Representation of the sequences surrounding exon X and the 
mutations introduces (m1: blue; m2: green; c.2991+1655A>G in red) in all the constructs 
generated; (C) Evaluation of the splicing pattern observed in these constructs after 
overexpression in two human (HEK293T and hTERT-RPE1) and two murine (mIMCD-3 
and B16-F10) cell lines. Amplification of actin (ACT) and rhodopsin (RHO) was used for 
normalization and to assess transfection efficiency, respectively. Milli-Q water (MQ) was 
used as negative control of the PCR. Semiquantitative analysis of the gels is shown in 
Supplementary Figure S2. 
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3. Discussion 
In this study, we have evaluated the recognition of cryptic splice sites and subsequent insertion of 
cryptic exons to CEP290 mRNA in a series of cell lines from different species, in order to better 
understand the splicing pattern observed in the humanized CEP290 mouse models [16]. Besides a clear 
differential recognition of a disease-associated pseudo-exon X between different species, we have 
shown that modifying splice-site sequences allows shifting the balance of multiple splice products, 
providing tools to better mimic the molecular and phenotypic characteristics of splice site mutations. 
Differences in splicing patterns among species due to tissue-specific and/or differential alternative 
splicing have been described in a few occasions [16–19]. Moreover, the retina is a tissue that displays  
a high degree of transcriptional activity and alternative splicing, without a full understanding of this 
transcriptional complexity [17,20–23]. The degree of alternative splicing appears to be directly 
correlated with the complexity of the organism, especially for those genes involved in neuronal and 
immunological development and/or processes [24,25]. Thus, the specificity of the splicing machinery 
and the signals involved vary not only among lineages, but also within mammals [24,26]. 
Using minigene constructs in a cellular system, we showed that we could mimic the aberrant 
CEP290 splicing that is observed in patient-derived cells [9]. Subsequent transfection of these 
minigene constructs in different murine cell lines consistently revealed a similar splicing behavior to 
the one described previously in our Cep290hum/hum and Cep290lca/lca mouse models [16]. To determine 
whether this recognition was exclusively occurring in humans, several cell lines derived from other 
species were assessed. The fact that the transcript containing exons 26 + X + 27 (the aberrant transcript 
robustly detected in LCA patients) was also well recognized in primate cells but not efficiently in other 
cell lines, suggests that either the primate spliceosome is more flexible in recognizing sequences 
differing from the consensus, or that other signals present within intron 26 as well as other molecular 
factors exclusively present in these species facilitate the recruiting of the spliceosome and thereby the 
insertion of exon X in the final CEP290 transcript. For instance, branch-site sequences can provide 
some plasticity in determining constitutive or alternative splicing, and it has been shown that these are 
low conserved between mouse and human [27]. In this context, although exon X-containing transcript 
levels appear to be similar in all the cell lines, these differences may explain why the aberrant 
transcript found in LCA patients is poorly recognized in non-primate cell lines. Interestingly, exon X 
appears to be mainly inserted together with exon Y, suggesting that a more complex co-recognition  
of splice signals determines the final transcript composition. Intriguingly, with exon Y occurs the 
opposite effect, it is well recognized in rodents but not endogenously in human fibroblast cells, neither 
from LCA patients nor from healthy individuals [16]. In human and primate cell lines however, some 
exon Y-containing transcripts were detected upon transfection of the minigene constructs, which may 
be explained by the overexpression of the construct. The same applies for exon Z; although it was not 
possible to detect this exon in fibroblast cells from human individuals, it was present in the retinas of 
the humanized mouse models, indicating that exon Z it is not solely an artifact of the overexpression. 
Together, the cellular system we used reflects the in vivo situation (Figure 1A), and although the 
overexpression of the constructs may result in some artificial splicing events, clear differences between 
species were observed. 
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The use of the constructs under the control of the CMV immediate-early promoter may add some 
variability in the expression levels of some of the cell lines. For instance, it is known that the CMV 
promoter is not optimal for fly cell lines, but works well in mammalian cell lines. In order to facilitate 
the comparison of all cell lines, we used the CMV promoter also in fly cells, which resulted in the 
expression of CEP290 transcripts, as well as rhodospin, indicating that both minigenes were expressed 
in this cellular model, but perhaps at lower levels than in the other cell lines. In addition, in all  
non-primate cell lines, the CEP290 expression detected was derived only from the minigenes, since the 
primers used are not capable of amplifying endogenous CEP290 due to several mismatches in the 
sequence relative to the genome of those species. In primate cell lines, however, endogenous CEP290 
was amplified, explaining ~20%–30% of the total CEP290 levels in some of the cell lines. This has 
been taken into account for the semiquantitative analysis. 
A “humanization” of animal models has been performed for several disorders [28–31], however  
to our knowledge all but ours [16] recapitulated the human splicing pattern, although this did not always 
lead to a phenotype (i.e., in a IKBKAP humanized mouse model) [32]. The fact that our mouse model 
did not show the aberrant splicing of CEP290 that is characteristic of the LCA-causing intronic 
mutation, prevents us to study the exact pathophysiological mechanisms as well as to test pre-clinical 
efficacy of AON-based splice correction therapy [9,33]. For this reason, we aimed to identify a 
suitable combination of acceptor and donor splice site sequences that would allow an efficient 
recognition of cryptic exon X by the mouse splicing machinery. The modification of only one of the 
splice sites was enough to increase the inclusion of exon X in primate cell lines, but not in mouse, even 
though the novel splice site sequences were highly similar to the consensus one. In mice, only the 
combination of both modifications was able to consistently enhance inclusion of the cryptic exon X. These 
findings could provide us with tools to generate a new humanized mouse model for CEP290-associated 
LCA, suitable to determine pre-clinical proof-of-concept of novel therapeutic strategies in vivo [9,33]. 
Together, our results highlight the complexity of the splicing process among species, and show the 
importance of taking into account these differences when generating animal models to mimic human 
disorders caused by splice mutations. 
4. Experimental Section 
4.1. Minigene Generation 
A PCR with primers located in CEP290 introns 25 (forward) and 27 (reverse) was performed on 
genomic DNA of healthy individuals and the PCR product was cloned into a pDONR vector using the 
Gateway system (primer sequences in Table 1). Via site-directed mutagenesis, the c.2991+1655A>G 
mutation was introduced. Both pDONR vectors (mutant and wild-type (WT)) were sequenced and 
cloned into the destination vector pCi-Neo-Rho-Splicing vector, a home-made vector that allows the 
cloning of the fragment of interest between exons 3 and 5 of RHO under the control of the cytomegalovirus 
immediate-early promoter [34], generating WT or LCA minigene constructs (Figure 1A). 
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4.2. Site-Directed Mutagenesis 
Forward and reverse primers were designed to modify specific nucleotides in the acceptor (m1) and 
donor splice (m2) sites of exon X. Site-directed mutagenesis was performed using the primers listed in 
Table 1 and the high fidelity Phusion Taq polymerase. The PCR program consisted of an initial step of 
2 min at 94 °C followed by 15 cycles: 94 °C for 30 s, 50 °C for 30 s and 72 °C for 12 min. Last step 
was the final extension for 15 min at 72 °C. 
4.3. Cell Lines 
All cell lines and culture conditions are described in Table 2. 
4.4. Transfection 
Cells (150,000–300,000, depending on the size of the cells) were seeded in 12-well plates and 
transfected the day after with FuGene (Promega, Madison, WI, USA) reagent (ratio 1:3) according  
to the manufacturer’s protocol. Medium was replaced after 24 h and cells were harvested 48 h  
post-transfection. Cells were transfected with 1 μg of the WT or LCA minigene for the assessment of 
the species-dependent recognition, and with WT, LCA or all the modified LCA minigenes for the more 
in depth study in human and murine cell lines. 
4.5. RT-PCR and Transcriptional Analysis 
RNA isolation was performed using the NucleoSpin RNA kit (Nucleospin RNA II, Macherey-Nagel, 
Düren, Germany) following manufacturer’s instructions. One microgram of the isolated RNA was 
used for cDNA synthesis using the iScript cDNA synthesis kit (Bio-Rad, Hercules, CA, USA). 
Subsequently, cDNA was diluted in H2O to a final concentration of 5 ng/μL and used for PCR 
analysis. All reaction mixtures (25 μL) contained 10 μM of each primer pair (Table 1), 2 μM of 
dNTPs, 1.5 mM MgCl2, 10% Q-solution (Qiagen, Venlo, The Netherlands), 1 U of Taq polymerase 
(Roche, Penzberg, Germany) and 25 ng of diluted cDNA. PCR conditions were 94 °C for 2 min, 
followed by 35 cycles of 20 s at 94 °C, 30 s at 58 °C and 30 s at 72 °C, with a final extension step of  
2 min at 72 °C. RHO was amplified as a measure to assess the transfection and transcription efficiency, 
whereas ACTN was amplified to serve as a loading control. All PCR products were resolved on 2% 
agarose gels. Bands were extracted from the agarose gel and purified using NucleoSpin Gel & PCR 
Clean-up (Macherey-Nagel). Bands were sent for Sanger sequencing, employing the same primers that 
were used in the PCR reaction. Semiquantitative analysis of the bands was performed using Image J 
software [35]. Values were first normalized against actin and subsequently against rhodopsin. 
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Table 2. Cell lines and growth conditions. 
Cell Line (Source) Animal Tissue of Origin Culture Medium Temp. 
Fibroblast  
(skin biopsy) 
Human Skin DMEM supplemented with 20% Fetal Calf Serum 
(FCS), 1% NaPyr, 100 U/mL penicillin and  
100 μg/mL streptomycin 
37 °C 
HEK293T  
(ATCC® CRL-3216™) 
Human Embryonic 
kidney 
DMEM supplemented with 10% Fetal Calf Serum 
(FCS), 1% NaPyr, 100 U/mL penicillin and  
100 μg/mL streptomycin 
37 °C 
hTERT-RPE1 
(ATCC® CRL-4000™) 
Human Eye DMEM:F10 (1:1) supplemented with 10% FCS,  
1% NaPyr, 100 U/mL penicillin and  
100 μg/mL streptomycin 
37 °C 
COS1  
(ATCC® CRL-1650™) 
Monkey Kidney DMEM supplemented with 10% FCS, 1% NaPyr, 
100 U/mL penicillin and 100 μg/mL streptomycin 
37 °C 
PK1  
(ATCC® CRL-101™) 
Pig Kidney DMEM supplemented with 5% FCS, 1% NaPyr,  
100 U/mL penicillin and 100 μg/mL streptomycin 
37 °C 
MDCK  
(ATCC® CRL-2935™) 
Dog Kidney DMEM supplemented with 5% FCS, 1% NaPyr,  
100 U/mL penicillin and 100 μg/mL streptomycin 
37 °C 
CHO  
(ATCC® CRL-61™) 
Hamster Ovary DMEM supplemented with 10% FCS, 1% NaPyr, 
100 U/mL penicillin and 100 μg/mL streptomycin 
37 °C 
mIMCD-3  
(ATCC® CRL-2123™) 
Mouse Kidney DMEM:F10 (1:1) supplemented with 10% FCS,  
1% NaPyr, 100 U/mL penicillin and  
100 μg/mL streptomycin 
37 °C 
B16-F10  
(ATCC® CRL-6475™) 
Mouse Skin MEM supplemented with 5% FCS,  
1% Non-essential amino acid (NEAA),  
1% NaPyr, 1.5% MEM vitamins,  
100 U/mL penicillin and 100 μg/mL streptomycin 
37 °C 
N2A  
(ATCC® CCL-131™) 
Mouse Brain DMEM supplemented with 10% FCS,  
1% L-Glutamine, 1% NaPyr, 1% NEAA,  
100 U/mL penicillin and 100 μg/mL streptomycin 
37 °C 
ATT20  
(ATCC® CCL-89™) 
Mouse Pituitary DMEM supplemented with 7% FCS, 7% HS,  
100 U/mL penicillin and 100 μg/mL streptomycin 
37 °C 
EL4  
(ATCC® TIB-39™) 
Mouse Lymphocyte Iscove’s medium supplemented with 5% FCS,  
100 U/mL penicillin and 100 μg/mL streptomycin 
37 °C 
S2  
(ATCC® CRL-1963™) 
Fly Embryo Schneider’s Drosophila medium supplemented  
with 10% heat-inactivated FCS,  
50 U/mL penicillin and 50 μg/mL streptomycin 
25 °C 
ATCC, American Type Culture Collection, Manassas, VA, USA. 
Supplementary Materials 
Supplementary materials can be found at http://www.mdpi.com/1422-0067/16/03/5285/s1. 
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